Rua Bioscience burns through $6.2m

Rua Bioscience burns through $6.2m
Rua: R&D spending up. (Image: Supplied)
Brent Melville
Listed medicinal cannabis firm Rua Bioscience almost doubled its cash burn rate for the year to June, recording a loss before tax of $6.17 million, from a loss of $3.59m last year.That was after research and development spending jumped to $1.9m, from $1.29m in 2020, reflecting the costs of developing the firm’s product lines, and investment into cultivation and manufacturing. The East Coast-based firm’s income came in the form of a government research and development grant of $357,366 and a covid wage subsidy of $91,636. It emp...

More Markets

NZME board told 'compromise or be rolled'
Markets

NZME board told 'compromise or be rolled'

Minority shareholders are falling in behind billionaire Jim Grenon's board coup.

NZ sharemarket steady after Ryman completes capital raise
Markets Market Close

NZ sharemarket steady after Ryman completes capital raise

The S&P/NZX 50 Index closed at 12,209.05, down 40.5 points or 0.33%.

Graham Skellern 13 Mar 2025
Underwriters left with $161m of Ryman stock
Property

Underwriters left with $161m of Ryman stock

Retail investors took up 42% of the shares offered to them in the capital raise.

Gregor Thompson 13 Mar 2025
NZ sharemarket falls 1.3% on uncertainty
Markets Market Close

NZ sharemarket falls 1.3% on uncertainty

The S&P/NZX 50 Index closed at 12,249.55, down 161.42 points or 1.3%.

Graham Skellern 12 Mar 2025